BCL2L1 and cancer: Although ABT-737 showed promising therapeutic properties in pre-clinical cell line-, primary cell- and animal-models against cancers over-expressing Bcl-2 or Bcl-xL [51], to date only two clinical trials for ABT-737 have been publicized (www.clinicaltrials.gov).